Press Releases

14th March 2019
Positive DSMC Review of Phase II Study for SNG001
25th February 2019
Preliminary statement of results for the year ended 31 December 2018
17th January 2019
Update on LOXL2 programme with Pharmaxis
22nd October 2018
Synairgen commences dosing in part 2 of its Phase II clinical trial in patients with COPD
12th October 2018
Result of General Meeting
25th September 2018
Result of Fundraise
25th September 2018
Proposed Fundraise to raise c.£2.9 million
25th September 2018
Interim results for the six months ended 30 June 2018
28th June 2018
Positive SNG001 Biomarker Data in COPD Patients
22nd June 2018
Result of Synairgen AGM
22nd June 2018
Synairgen Safety Data with SNG001 in COPD Patients
17th May 2018
Posting of Annual Report and Notice of AGM
15th March 2018
Preliminary statement of results for the year ended 31 December 2017
7th February 2018
Synairgen starts dosing in phase II COPD study
14th December 2017
Update on LOXL2 Programme & Phamaxis Collaboration
27th December 2017
Data update for clinical trial of inhaled interferon beta and clinical plan for COPD
27th September 2017
Interim results for the six months ended 30 June 2017
6th September 2017
LOXL2 Inhibitor Update
28th June 2017
Result of 2017 Annual General Meeting
5th June 2017
Posting of Annual Report and Notice of AGM
17th May 2017
Preliminary statement of results for the year ended 31 December 2016
27th April 2017
AZD9412 Update
10th March 2017
Additional positive data in lung fibrosis
12 October 2016
AZD9412 Clinical Trial Update
22 September 2016
Interim results for the six months ended 30 June 2016
08 September 2016
Notice of Interim Results
14 June 2016
Results of 2016 Annual General Meeting
17 May 2016
Posting of Annual Report and Notice of AGM
22 March 2016
Preliminary results for the year ended 31 December 2015
22 March 2016
Positive LOXL2 results
03 March 2016
Notice of Preliminary Results
16 September 2015
Interim results for the six months ended 30 June 2015
21 August 2015
Notice of Interim Results
05 August 2015
Research collaboration with Pharmaxis in IPF
22 July 2015
AstraZeneca commences AZD9412 Phase II trial in severe asthma
22 June 2015
Results of 2015 Annual General Meeting
15 May 2015
Notice of 2015 AGM
22 April 2015
Posting of annual report and accounts
03 March 2015
Preliminary results for the year ended 31 December 2014
25 September 2014
Interim results for six months ended 30 June 2014
17 September 2014
Notice of interims 17 Sept 14
04 July 2014
Placing
12 June 2014
AstraZeneca licence deal
09 June 2014
Results of Annual General Meeting
16 May 2014
Notice of 2014 AGM
09 May 2014
Posting of annual report and accounts
20 March 2014
Preliminary results for the year ended 31 December 2013
05 March 2014
Licensing update, placing to raise £1.5 million and notice of results
12 August 2013
Interim results for the six months ended 30 June 2013
18 July 2013
Positive anti-inflammatory and anti-viral data
10 June 2013
Results of Annual General Meeting
09 May 2013
Notice of 2013 AGM
09 April 2013
Posting of annual report and accounts
13 February 2013
Preliminary results for the year ended 31 December 2012
05 December 2012
Trading Update
30 October 2012
Director’s dealing
10 August 2012
Interim results for the six months ended 30 June 2012
18 July 2012
Placing
25 June 2012
Results of Annual General Meeting
22 May 2012
Professor Stephen Holgate given prestigious award
19 April 2012
Positive Phase II asthma clinical trial data
02 March 2012
Notice of Report and Accounts
01 February 2012
Preliminary results for the six months ended 31 December 2011
30 January 2012
Notice of results
12 December 2011
Director’s dealing
08 December 2011
End of recruitment in Phase II asthma trial
25 November 2011
Positive viral pneumonia study results
10 November 2011
Result of AGM
18 October 2011
Notice of Annual Report and Accounts and Annual General Meeting
13 September 2011
Preliminary results for the year ended 30 June 2011
09 September 2011
Change of NOMAD
18 July 2011
Japanese patent to be granted
28 June 2011
Phase II asthma study – Interim Review and update
13 June 2011
Result of General Meeting and Closing of the Fundraising
27 May 2011
Fundraising
04 May 2011
In vitro antiviral activity of interferon beta against H5N1 (bird flu)
01 February 2011
Interim results for the six months ended 31 December 2010
03 November 2010
Result of AGM
19 October 2010
Allowance of US Patent Application for use of interferon beta to treat rhinovirus infection in the elderly
08 October 2010
Notice of Annual Report and Accounts and Annual General Meeting
29 July 2010
Preliminary results for the year ended 30 June 2010
27 July 2010
Notice of results
28 June 2010
Directorate change
17 May 2010
New data for the treatment of ‘severe’ influenza lung infection
06 May 2010
Interferon beta patent granted in Europe
01 April 2010
Commencement of Phase II clinical trial
08 February 2010
Interim results for the six months ended 31 December 2009
12 November 2009
Successful outcome of Phase I safety and antiviral ‘proof of mechanism’ biomarker study of inhaled interferon beta in asthmatic subjects
11 November 2009
Result of AGM
09 November 2009
In vitro antiviral activity of interferon beta against 2009 H1N1 (swine flu)
26 October 2009
Notice of Investor Conference
14 October 2009
Notice of Annual Report and Accounts and Annual General Meeting
04 September 2009
Preliminary results for the year ended 30 June 2009
04 September 2009
Directorate change
04 September 2009
US interferon beta patent granted
02 September 2009
Notice of results
30 June 2009
Total voting rights
15 June 2009
Second closing of fundraising
12 June 2009
Result of General Meeting
27 May 2009
Fundraising announcement
01 April 2009
Preliminary biomarker data
31 March 2009
Change of NOMAD
26 March 2009
Interim results for the six months ended 31 December 2008
24 March 2009
Interim results announcement date
17 March 2009
Progress update: Clinical Trial with Interferon Beta in Asthmatic Volunteers
13 November 2008
Result of AGM
07 November 2008
Change of NOMAD
31 October 2008
Total voting rights
20 October 2008
Director shareholdings
10 October 2008
Posting of 2008 annual report
08 October 2008
Change of Broker and Nominated Adviser Name
22 September 2008
Research update on inhaled interferon beta programme
04 August 2008
Director shareholdings
31 July 2008
Preliminary results for the year ended 30 June 2008
29 July 2008
Commencement of clinical trial
14 July 2008
Preliminary results announcement date
23 May 2008
Presentation of data at American Thoracic Society (ATS)
13 March 2008
Director shareholding
12 March 2008
Interim Results for the six months ended 31 December 2007
25 February 2008
Interim results announcement date
11 February 2008
Patent granted for Lung Barrier Screen Test
12 December 2007
Research collaboration with Wayne State University
15 November 2007
Result of AGM
12 November 2007
Contract with Alpha Biologics
31 October 2007
Director shareholding
28 September 2007
Licence and supply agreement for interferon beta from Rentschler
26 September 2007
Preliminary results for the year ended 30 June 2007
20 August 2007
Preliminary results announcement date
17 August 2007
AIM Rule 26
16 August 2007
Change of adviser
12 June 2007
Successful Outcome of Phase I Clinical Study of Inhaled Interferon Beta
19 March 2007
Interim Results for the six months ended 31 December 2006
13 February 2007
Interim results announcement date
11 December 2006
Total Voting Rights announcement
30 November 2006
Director shareholding
15 November 2006
Novel Peptide treatment of asthma
15 November 2006
Results from AGM
08 November 2006
Director shareholding
18 September 2006
2006 Preliminary Statement
01 September 2006
Preliminary results announcement date
14 August 2006
Interferon lambda intellectual property licensed from Imperial Innovations
24 May 2006
New research signals second indication for Interferon beta programme in COPD
11 April 2006
Synairgen PLC board changes
23 February 2006
Interim Results for the six months ended 31 December 2005
01 January 2006
Notification of Interim Results
23 November 2005
Director/PDMR Shareholding
16 November 2005
Result of AGM
09 November 2005
Interferon-Beta Enters Clinic
02 November 2005
Change of Adviser
01 September 2005
Preliminary Results for the year ended 30 June 2005
23 March 2005
Research identifies potential new therapy for asthmatics to combat colds (Media Information)
09 March 2005
Collaboration with Centocor
09 March 2005
Interim Results to 31 Dec 2004
20 October 2004
Successful £10.5 million placing
01 October 2004
Intention to float on AIM
01 June 2004
Collaboration with Merck
01 January 2004
Collaboration with CAT

Investors